

Complications and Outcomes of Obese Patients Hospitalized with COVID-19

Anita Shallal MD¹, Austin Morrison PharmD², Indira Brar MD¹, Geehan Suleyman MD¹ Henry Ford Health System¹, Detroit, MI; Moffitt Cancer Center, Tampa FL²

INTRODUCTION

- Coronavirus disease 2019 (COVID-19) has greatly affected the US, where obesity is present in over 40% of the population
- Evidence suggests that obesity is associated with a higher risk of developing severe disease and complications
- We explored the relationship between body mass index (BMI) and outcomes in hospitalized patients with COVID-19

METHODS

- Study Design
 - Retrospective cohort, five-hospital health system
- Subjects
 - Study population included obese (BMI \geq 30) and non-obese (BMI < 30) patients hospitalized with COVID-19 at Henry Ford Health System from March 2020 through May 2020
- •Analysis
 - Performed using SPSS software version 24.0 (IBM)
- •Primary Endpoint
 - Evaluate outcomes and complications, in particular mechanical ventilation

RESULTS

- Younger patients were more obese compared to older patients
- Although 37% of obese patients were intubated, obesity was not a significant risk factor for mechanical ventilation (MV)
- In the regression analysis, age over 60 (p=0.004), tachypnea at admission (p<0.001), acute kidney injury (p<0.001), and diabetes (p=0.010) were significantly associated with need for MV, but not BMI

	BMI < 30 N=261 (%)	$BMI \ge 30$ N=324 (%)	P value
Demographics			
Male gender	132 (50.6)	170 (52.5)	0.649
Black race	146 (55.9)	254 (78.4)	< 0.001
Age (median, IQR)	69 (56, 76.75)	54.5 (44.75, 62.25)	< 0.001
Age >60	212 (81.2)	161 (49.7)	< 0.001
BMI (kg/m ² median, IQR)	26 (23.1-28)	36.5 (32.7-41.7)	< 0.001
Comorbid conditions			
Asthma	24 (9.2)	44 (13.6)	0.100
COPD	56 (21.5)	55 (17.0)	0.169
Obstructive sleep apnea	10 (3.8)	66 (20.4)	< 0.001
Diabetes mellitus	91(34.9)	152 (46.9)	0.003
Hypertension	188 (72)	249 (76.9)	0.182
Chronic kidney disease	139 (53.3)	150 (46.3)	0.094
ESRD	20 (7.7)	18 (5.6)	0.292
Solid organ transplantation	6 (2.3)	8 (2.5)	0.893
Coronary artery disease	51 (19.5)	55 (17)	0.423
Congestive heart failure	51 (19.5)	52 (16)	0.270
Cancer	51 (19.5)	30 (9.3)	< 0.001
Tobacco use	99 (37.9)	99 (30.5)	0.061
Baseline respiratory vital			
signs	94 (90,96)	93 (88.75, 95)	0.493
Oxygen saturation	158 (60.5)	180 (55.6)	0.225
Respiratory rate > 22			
Treatment			
Antibiotics (ED)	179 (70.2)	255 (79.2)	0.015

[BMI, body mass index; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease]

DECILITO

RESULIS Table 2. Comparison of Treatment, Complications and Outcomes of patients with BMI < 30 and BMI > 30				
Complications				
Mechanical ventilation	89 (34.1)	121 (37.3)	0.416	
Vasopressors for shock	43 (16.5)	85 (26.2)	0.004	
RRT	9 (3.4)	30 (9.3)	0.005	
ARDS	83 (31.8)	118 (36.5)	0.231	
Acute kidney injury	131 (50.2)	165 (50.9)	0.860	
Discharged	127	215		
Disposition				
Home	104 (81.9)	199 (92.6)	0.005	
Rehab facility	14 (11)	13(6)	0.099	
Other	9 (7.1)	3 (1.4)	0.011	
30-day hospital	18 (14.3)	10 (4.7)	0.001	
readmission				
30-day mortality	133 (51.0)	93 (29.0)	< 0.001	

[BMI, body mass index; RRT; renal replacement therapy, ARDS, acute respiratory distress syndrome]

CONCLUSION

- In our cohort, a high frequency of obesity is noted among black and younger patients
- Obese patients were more likely to require intensive treatments, including renal replacement therapy and vasopressors, but not MV
- Complications and outcomes in COVID-19 should be further evaluated by BMI categories

Disclosure: All authors report no conflicts of interest

Anita Shallal, MD 2799 W. Grand Blvd, Detroit, MII 48202 ashalla2@hfhs.org 313-850-7032